Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-06-08T16:05:23.863Z Has data issue: false hasContentIssue false

Chapter 6 - Characteristics and Principles of Master Protocols

from Part III - Basic Ingredients for Master Protocols

Published online by Cambridge University Press:  20 March 2023

Jay J. H. Park ,
Edward J. Mills  and
J. Kyle Wathen
By
Jay J. H. Park ,
J. Kyle Wathen  and
Edward J. Mills
Jay J. H. Park
Affiliation:
McMaster University, Ontario
Edward J. Mills
Affiliation:
McMaster University, Ontario
J. Kyle Wathen
Affiliation:
Cytel, Cambridge, Massachusetts
Get access

Summary

In this chapter, we discuss the key concepts, terminologies, and principles of master protocols. The term ‘master protocol’ is often misunderstood and misused. This term refers to a single overarching protocol document that is developed with the intention of evaluating multiple interventional hypotheses. ‘Master protocol’ itself does not refer to a specific type of clinical trial. There are three types of clinical trials that are conducted using the master protocol framework: platform trials, basket trials, and umbrella trials. While master protocols can naturally extend to adaptive trial designs, the use of adaptive trial designs is not a defining feature of master protocols nor of platform, basket, and umbrella trials. Master protocols implement common screening, trial systems, and standardised operating procedures across multiple trial institutions under one centralised governance model. In addition to statistical efficiencies, operational efficiencies can be gained by adopting the master protocol framework.

Keywords

master protocolsbasket trialsumbrella trialsplatform trialsprecision medicineprecision oncologycore protocol
Type
Chapter
Information
Introduction to Adaptive Trial Designs and Master Protocols , pp. 63 - 72
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Woodcock, J, LaVange, LM. Master protocols to study multiple therapies, multiple diseases, or both. N Eng J Med. 2017;377(1):62–70.Google Scholar
Park, JJH, Siden, E, Zoratti, MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572.Google Scholar
Siden, EG, Park, JJ, Zoratti, MJ, et al. Reporting of master protocols towards a standardized approach: a systematic review. Contemp Clin Trials Commun. 2019;15:100406.Google Scholar
Park, JJH, Harari, O, Dron, L, et al. An overview of platform trials with a checklist for clinical readers. J Clin Epidemiol. 2020;125:1–8.Google Scholar
Mills, EJ, Thorlund, K, Ioannidis, JP. Demystifying trial networks and network meta-analysis. BMJ. 2013;346:f2914.Google Scholar
Redman, MW, Allegra, CJ. The master protocol concept. Semin Oncol. 2015;42(5):724–30.Google Scholar
Hirakawa, A, Asano, J, Sato, H, Teramukai, S. Master protocol trials in oncology: review and new trial designs. Contemp Clin Trials Commun. 2018;12:1–8.Google Scholar
Park, JJH, Hsu, G, Siden, EG, Thorlund, K, Mills, EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70(2):125–37.Google Scholar
United States Department of Health and Human Services, Food and Drug Administration. Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry. United States Department of Health and Human Services; 2022. www.fda.gov/media/120721/download.Google Scholar
United States Department of Health and Human Services, Food and Drug Administration. Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry (Draft Guidance). United States Department of Health and Human Services; 2018. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM621817.pdf.Google Scholar
Zhou, X, Lei, L, Liu, J, et al. A systems approach to refine disease taxonomy by integrating phenotypic and molecular networks. EBioMedicine. 2018;31:79–91.Google Scholar
Mullauer, L. Milestones in pathology-from histology to molecular biology. Memo. 2017;10(1):42–5.Google Scholar
Zhang, H, Zeng, Z, Mukherjee, A, Shen, B. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn. 2018;18(10):867–86.Google Scholar
Abrams, J, Conley, B, Mooney, M, et al. National Cancer Institute’s Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014:71–6.CrossRefGoogle Scholar
Heckman-Stoddard, BM, Smith, JJ. Precision medicine clinical trials: defining new treatment strategies. Semin Oncol Nurs. 2014;30(2):109–16.Google Scholar
Kumar-Sinha, C, Chinnaiyan, AM. Precision oncology in the age of integrative genomics. Nat Biotechnol. 2018;36(1):46–60.Google Scholar
National Institutes of Health All of US Research Program. About the All of Us Research Program. Cited 2019. https://allofus.nih.gov/about/about-all-us-research-programGoogle Scholar
Clinical Trials Transformation Initiative. Master Protocol Studies; 2021 https://ctti-clinicaltrials.org/our-work/novel-clinical-trial-designs/master-protocol-studies/Google Scholar
Berry, SM, Connor, JT, Lewis, RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619–20.CrossRefGoogle ScholarPubMed
Adaptive Platform, Trials C. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov. 2019;18(10):797–807.CrossRefGoogle Scholar
Park, JJH, Dron, L, Mills, EJ. Moving forward in clinical research with master protocols. Contemp Clin Trials. 2021;106:106438.Google Scholar
Vanderbeek, AM, Bliss, JM, Yin, Z, Yap, C. Implementation of platform trials in the COVID-19 pandemic: a rapid review. Contemp Clin Trials. 2022;112:106625.Google Scholar
Dean, NE, Gsell, PS, Brookmeyer, R, et al. Creating a framework for conducting randomized clinical trials during disease outbreaks. N Engl J Med. 2020;382(14):1366–9.CrossRefGoogle ScholarPubMed
Schiavone, F, Bathia, R, Letchemanan, K, et al. This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. Trials. 2019;20(1):264.Google Scholar
Fogel, DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156–64.Google Scholar
Antoniou, M, Kolamunnage-Dona, R, Wason, J, et al. Biomarker-guided trials: challenges in practice. Contemp Clin Trials Commun. 2019;16:100493.Google Scholar
Preston, J, VanZeeland, A, Peiffer, D. Innovation at Illumina: the road to the $600 human genome. Nature (Illumia). 2021.Google Scholar
Lam, VK, Papadimitrakopoulou, V. Master protocols in lung cancer: experience from Lung Master Protocol. Curr Opin Oncol. 2018;30(2):92–7.Google Scholar
Ferrarotto, R, Redman, MW, Gandara, DR, Herbst, RS, Papadimitrakopoulou, VA. Lung-MAP – framework, overview, and design principles. Chin Clin Oncol. 2015;4(3):36.Google Scholar
Houston, L, Yu, P, Martin, A, Probst, Y. Heterogeneity in clinical research data quality monitoring: a national survey. J Biomed Inform. 2020;108:103491.Google Scholar
Kuchinke, W, Ohmann, C, Yang, Q, et al. Heterogeneity prevails: the state of clinical trial data management in Europe – results of a survey of ECRIN centres. Trials. 2010;11:79.Google Scholar
Remap-Cap Investigators, ACTIV-4a Investigators, Attacc Investigators, Goligher, EC, Bradbury, CA, McVerry, BJ, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–89.Google Scholar
Thorlund, K, Dron, L, Park, J, et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digit Health. 2020;2(6):e286–e7.Google ScholarPubMed
Dillman, A, Park, JJH, Zoratti, MJ, et al. Reporting and design of randomized controlled trials for COVID-19: a systematic review. Contemp Clin Trials. 2021;101:106239.Google Scholar
Park, JJ, Mogg, R, Smith, GE, et al. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob Health. 2021;9(5):e711–e20.Google Scholar
NIHR. Recruiting patients for clinical trials for COVID-19 therapeutics. 2020. www.nihr.ac.uk/news/uks-chief-medical-officers-urge-hospitals-to-recruit-60-of-eligible-covid-19-patients-into-recovery-trial/25515Google Scholar
Recovery Collaborative Group, Horby, P, Lim, WS, Emberson, JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.Google Scholar
Berry, DA, Graves, T, Connor, J, et al. Adaptively randomized seamless-phase multiarm platform trial: Glioblastoma Multiforme Adaptive Global Innovative Learning Environment (GBM AGILE). Cancer Research. 2017;77(13 Supplement 1).Google Scholar
Rugo, HS, Olopade, OI, DeMichele, A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Eng J Med. 2016;375(1):23–34.Google Scholar
Barker, AD, Sigman, CC, Kelloff, GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97–100.Google Scholar
Papadimitrakopoulou, V, Lee, JJ, Wistuba, II, et al. The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(30):3638–47.Google Scholar
Tam, AL, Kim, ES, Lee, JJ, et al. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013;8(4):436–42.Google Scholar
Kim, ES, Herbst, RS, Wistuba, II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44–53.Google Scholar
Wang, H, Yee, D. I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer. Curr Breast Cancer Rep. 2019;11(4):303–10.CrossRefGoogle ScholarPubMed
Bogin, V. Master protocols: new directions in drug discovery. Contemp Clin Trials Commun. 2020;18:100568.Google Scholar
Ali, A, Hoyle, A, Haran, AM, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2021;7(4):555–63.Google Scholar
Cortazar, P, Geyer, CE. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015;22(5):1441–6.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×